Animal Care Achieves Record Sales in May 2024 for its vetIQure™ TSE system
Scandinavian ChemoTech is proud to announce that its Animal Care operations has achieved another record month of sales in May 2024. This exceptional performance underscores the growth and the increasing market demand for its innovative veterinary solution; the vetIQure™ TSE (Tumour Specific Electroporation™) system.
The remarkable sales figures for May are attributed to the growing popularity and successful adoption of ChemoTech's vetIQure TSE system across key markets in North America and Europe, including previously announced significant new orders totalling more than EUR 92,000 from Germany and Canada.
"We are thrilled to report this important sales milestone." said Mohan Frick, CEO of Scandinavian ChemoTech. "The record sales in May are a testament to the hard work and dedication of our Animal Care team. This success reflects the trust our clients place in our products and our commitment to delivering the highest standards in veterinary care."
The increasing success and expanding recognition in Europe and North America highlight the advanced treatment capabilities of the vetIQure TSE system. The system is noted for its time and cost efficiency, as well as its minimally invasive nature, making it suitable for treating various types of cancer in both horses and small pets. Additionally, it can often be performed under sedation and local anaesthesia.
For more information about ChemoTech, its Animal Care Division and the vetIQure™ TSE system, please visit www.chemotech.se or www.vetIQure.com
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 04-06-2024 14:45 CET.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.